File Download
  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Pharmacogenetic study of antipsychotic–induced lipid and BMI changes in Chinese schizophrenia patients: A Genome-Wide Association Study

TitlePharmacogenetic study of antipsychotic–induced lipid and BMI changes in Chinese schizophrenia patients: A Genome-Wide Association Study
Authors
Issue Date19-Aug-2025
PublisherSpringer Nature [academic journals on nature.com]
Citation
Translational Psychiatry, 2025, v. 15 How to Cite?
AbstractSecond-generation antipsychotics (SGAs) are widely used to treat schizophrenia (SCZ), but they often induce metabolic side effects like dyslipidemia and obesity. We conducted genome-wide association studies (GWASs) to identify genetic variants associated with SGA-induced lipid and BMI changes in Chinese SCZ patients. A longitudinal cohort of Chinese SCZ receiving SGAs was followed for up to 18.7 years (mean = 5.7 years, SD = 3.3 years). We analysed the patients’ genotypes (N = 669), lipid profiles, and BMI using 19 316 prescription records and 3 917 to 7 596 metabolic measurements per outcome. Linear mixed models were employed to evaluate seven SGAs’ random effects on metabolic changes for each patient, followed by GWAS and gene set analyses with Bonferroni and FDR correction. Five SNPs achieved p-value < 5 × 10−08 before multiple testing correction: rs6532055 (ABCG2) linked to olanzapine-induced LDL changes, rs2644520 (near SORCS1) linked to aripiprazole-induced triglyceride changes, rs115843863 (near UPP2) linked to clozapine-induced HDL changes, rs2514895 (near KIRREL3) linked to paliperidone-induced LDL changes, and rs188405603 (SLC2A9) linked to quetiapine-induced triglyceride changes. These five SNPs passed FDR correction at 0.2 but not Bonferroni-corrected genome-wide significance threshold (p-value < 3.125 × 10−10) for 160 GWAS analyses. Gene-based analysis revealed six genome-wide significant genes after Bonferroni correction (p-value < 2.73 × 10−6): ABCG2, APOA5, ZPR1, GCNT4, MAST2, and CRTAC1. Four gene sets were significantly associated with SGA-induced metabolic side effects. In summary, this pharmacogenetic GWAS identified several genetic variants potentially associated with SGA-induced metabolic side effects, potentially informing personalized treatment strategies to minimize metabolic risk in SCZ patients. Given our limited sample size, further replications are required to confirm the findings.
Persistent Identifierhttp://hdl.handle.net/10722/366847
ISSN
2023 Impact Factor: 5.8
2023 SCImago Journal Rankings: 2.203

 

DC FieldValueLanguage
dc.contributor.authorWong, Kenneth Chi-Yin-
dc.contributor.authorLeung, Perry Bok-Man-
dc.contributor.authorLee, Benedict Ka-Wa-
dc.contributor.authorZheng, Zoe Zi-Yu-
dc.contributor.authorTsang, Emily Man-Wah-
dc.contributor.authorLiu, Meng-Hui-
dc.contributor.authorLee, Kelly Wing-Kwan-
dc.contributor.authorRao, Shi-Tao-
dc.contributor.authorSham, Pak-Chung-
dc.contributor.authorLui, Simon Sai-Yu-
dc.contributor.authorSo, Hon-Cheong-
dc.date.accessioned2025-11-26T02:50:30Z-
dc.date.available2025-11-26T02:50:30Z-
dc.date.issued2025-08-19-
dc.identifier.citationTranslational Psychiatry, 2025, v. 15-
dc.identifier.issn2158-3188-
dc.identifier.urihttp://hdl.handle.net/10722/366847-
dc.description.abstractSecond-generation antipsychotics (SGAs) are widely used to treat schizophrenia (SCZ), but they often induce metabolic side effects like dyslipidemia and obesity. We conducted genome-wide association studies (GWASs) to identify genetic variants associated with SGA-induced lipid and BMI changes in Chinese SCZ patients. A longitudinal cohort of Chinese SCZ receiving SGAs was followed for up to 18.7 years (mean = 5.7 years, SD = 3.3 years). We analysed the patients’ genotypes (N = 669), lipid profiles, and BMI using 19 316 prescription records and 3 917 to 7 596 metabolic measurements per outcome. Linear mixed models were employed to evaluate seven SGAs’ random effects on metabolic changes for each patient, followed by GWAS and gene set analyses with Bonferroni and FDR correction. Five SNPs achieved p-value < 5 × 10−08 before multiple testing correction: rs6532055 (ABCG2) linked to olanzapine-induced LDL changes, rs2644520 (near SORCS1) linked to aripiprazole-induced triglyceride changes, rs115843863 (near UPP2) linked to clozapine-induced HDL changes, rs2514895 (near KIRREL3) linked to paliperidone-induced LDL changes, and rs188405603 (SLC2A9) linked to quetiapine-induced triglyceride changes. These five SNPs passed FDR correction at 0.2 but not Bonferroni-corrected genome-wide significance threshold (p-value < 3.125 × 10−10) for 160 GWAS analyses. Gene-based analysis revealed six genome-wide significant genes after Bonferroni correction (p-value < 2.73 × 10−6): ABCG2, APOA5, ZPR1, GCNT4, MAST2, and CRTAC1. Four gene sets were significantly associated with SGA-induced metabolic side effects. In summary, this pharmacogenetic GWAS identified several genetic variants potentially associated with SGA-induced metabolic side effects, potentially informing personalized treatment strategies to minimize metabolic risk in SCZ patients. Given our limited sample size, further replications are required to confirm the findings.-
dc.languageeng-
dc.publisherSpringer Nature [academic journals on nature.com]-
dc.relation.ispartofTranslational Psychiatry-
dc.rightsThis work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.-
dc.titlePharmacogenetic study of antipsychotic–induced lipid and BMI changes in Chinese schizophrenia patients: A Genome-Wide Association Study-
dc.typeArticle-
dc.description.naturepublished_or_final_version-
dc.identifier.doi10.1038/s41398-025-03499-w-
dc.identifier.volume15-
dc.identifier.eissn2158-3188-
dc.identifier.issnl2158-3188-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats